Executive VP and Head of R&D · RELMADA THERAPEUTICS, INC. (RLMD)

Thomas Wessel

FY2020 is the first fiscal year CompBrief holds for Thomas Wessel as a named executive officer of RELMADA THERAPEUTICS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,184,751

Salary $384,549Stock awards $0Bonus $50,000

1st of 5 named executive officers at Relmada Therapeutics by FY2020 total.

5 named officers on file for RELMADA THERAPEUTICS, FY2020

Thomas Wessel’s pay file — $29

  • 1 fiscal year of pay, line by line
  • RLMD’s disclosed peer group of 12 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how RELMADA THERAPEUTICS’s whole pay program stands against its peers

  • RELMADA THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RLMD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 31, 2021 (DEF 14A).

Free

Get Thomas Wessel’s full pay file as a PDF — free

More than this page: up to 10 years of Thomas’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Thomas Wessel compensation by year

RELMADA THERAPEUTICS Summary Compensation Table · the one fiscal year held
In US dollars, as RELMADA THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$384,549
Bonus$50,000
Stock awards$0
Option awards$483,762
Non-equity incentive$0
Pension and deferred compensation$0
All other$266,440
Total$1,184,751

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RELMADA THERAPEUTICS, INC. DEF 14A filed March 31, 2021, accession 0001213900-21-019299, and prior-year filings. Open the filing on EDGAR.

How this page was built: the RELMADA THERAPEUTICS, INC. filed document, accession 0001213900-21-019299. Every figure is read from that document and cited to the page and table it appears in. Filed March 31, 2021.

RELMADA THERAPEUTICS’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Thomas Wessel · this pageExecutive VP and Head of R&D$1,184,751
Sergio TraversaChief Executive Officer and Director$900,000
Maged ShenoudaChief Financial Officer$676,750
Charles EnceChief Accounting and Compliance Officer$453,750
Ottavio VitoloSenior Vice President, Head$313,415

The full RELMADA THERAPEUTICS compensation record

free company brief

This page is one person within RELMADA THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the RELMADA THERAPEUTICS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RELMADA THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Thomas Wessel's compensation dossier · One-time report. No refunds.